2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 260-262
Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pediatric, Young Adult
PAPER

1095 Longitudinal changes in neurocognitive function following CAR T-cell therapy for B-cell non-Hodgkin lymphoma

Amaris Karin Balitsky, MD MSc, Gregory Pond, PhD2, Gwynivere Davies, MD MPH3, Joanne M Britto, MD4, Graeme Fraser, MD, MSc, FRCPC5, Tom Kouroukis, MD, MSc, FRCPC6
1 Escarpment Cancer Research Institute, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
2 Escarpment Cancer Research Institute, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
3 Escarpment Cancer Research Institute, Hamilton, Ontario, Canada, Juravinski Cancer Centre, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
4 Juravinski Cancer Centre, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
5 Juravinski Cancer Centre, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
6 Juravinski Cancer Centre, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada

Introduction: The effects of CART therapy on long-term cognition is unknown. We conducted a prospective study using a battery of neurocognitive measures in patients with non-Hodgkin lymphoma (NHL) receiving CART therapy, prior to and 1 year following CART infusion.

Objectives: 1. Assess the feasibility of collecting longitudinal cognition measures in CART recipients. 2. Explore changes in cognition from baseline (pre-lymphodepleting (LD) chemotherapy) and 1 year following CART infusion.

Methods: This was a prospective cohort pilot study of 60 CART recipients conducted at the Juravinski Hospital and Cancer Centre, in Hamilton, Ontario. Eligible patients were those with NHL receiving standard of care CART therapy. Patients with known cognitive impairment or an inability to read and write English were excluded. Objective Cognition was measured using a battery of tests, including the Hopkins Verbal Learning Test-Revised (HVLTR) to measure memory, the Trail Making Test (TMT) to measure processing speed and attention, and the Controlled Oral Word Association test (COWA) to measure verbal fluency. Subjective cognition was measured using FACT-Cog, a patient-reported cognition measure. This battery was administered at baseline prior to receiving CART and 12-months following CART infusion. Data collected included, demographics, treatment, and toxicity information.  The local Hamilton Integrated Research Ethics Board approved this study.

Results: Between January 19th, 2024 and June 30th, 2026, 60 patients were enrolled into the study. Median age was 67 yrs. (range 32-84). 21 (35%) were female. Underlying diagnosis was DLBCL in 40 (66.7%), FL in 10 (16.7%), MCL in 3 (5.0%), transformed FL in 3 (5.0%) and marginal zone lymphoma in 4 (6.7%) patients. CART products included axicabtagene ciloleucel 52 (86.7%), brexucabtagene autoleucel 3 (5.0 %) lisocabtagene maraleucel 3 (5.0%) and tisagenlecleucel 2 (3.3%). Bridging was administered in 42 (70.0%) patients intended to receive CART therapy. Bridging therapies included corticosteroids 7 (16.7%), chemotherapy 26 (61.9%) and radiation therapy 16 (26.7%). Median pre-LD LDH was 219 (range 138-708). CRS of any grade occurred in 57 patients, including Grade 1–2 events in 55 (91.7%) and Grade 3–4 events in 2 (3.3%). ICANS of any grade occurred in 31 patients, including Grade 1–2 events in 22 (36.7%), Grade 3–4 events in 8 (13.3%), and one Grade 5 event (1.7%). Eight CART recipients (14.6%) required ICU admission. The 90-day overall response rate (ORR) was 75%.

All patients (100%) completed baseline neuro-cognitive measures; 47 (78.3%) completed 12m follow-up. Prior to 12m follow-up, 1 died from CART-related toxicity, 11 died from progressive disease, and 1 was inappropriate to approach as was being palliated.

The maximum Lawton Instrumental Activities of Daily Living score of 8 was achieved in 52 (86.7%). Similarly, Katz Activities of Daily Living scores indicated preserved basic functional status, with 54  (90%) scoring 6. Comorbidity burden was generally low, as reflected by the Charlson Comorbidity Index: 40 (66.7%) had a score of 0, 11 (18.3%) had a score of 1, and 9 (15.0%) had scores of 2 or higher.

Higher scores indicate better memory for HVLTR. Median HVLTR scores for total and delayed recall were stable; median total recall was 22 (IQR 19.5-25) at baseline to 25 (IQR 20,28) at 12m; median change was 2 (-2,4). Median delayed recall was 8 (IQR 7,10) at baseline to 9 (IQR 8,10) at 12m; median change was 1 (IQR -1,2). Lower scores, or completion times, reflect faster processing speed (Part A) and better attention (Part B) for the TMT. Median TMT part A scores were unchanged from 27 (IQR 24, 34) at baseline to 27 (IQR 21, 33) at 12m; median change was 0.6 (IQR -2.2, 5.3). Median TMT part B scores were unchanged from 66 (IQR 49, 86) at baseline to 58 (IQR 44, 79) at 12m; median change was -0.2 (IQR -8.7, 11.7). Higher scores indicate better verbal fluency for COWA. Median COWA scores were stable from 22 (IQR 19,26) at baseline to 24 (IQR 19,26) at 12m; median change was 0 (IQR -2,3).

Conclusions: Longitudinal cognitive assessment in CART recipients was feasible. Objective cognitive function remained stable from pre-LD chemotherapy to 12 months following CART infusion, suggesting no evidence of long-term cognitive decline over the first year. Further analyses of patient-reported cognitive changes and ICANS-related differences will be reported.

Amaris Karin Balitsky, MD MSc: BMS - Honoraria; Roche - Honoraria; Abbvie - Honoraria; BeOne - Honoraria; Kite/Gilead - Honoraria; Incyte - Honoraria; BMS - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony)